Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression

BJU International

Volumn 107, Issue 9, 2011, Pages 1488-1499

  Turney, Benjamin W ^b   Turner, Gareth D H ^a   Brewster, Simon F ^a   MacAulay, Valentine M ^b,c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

androgen deprivation; immunohistochemistry; prostate cancer; type 1 IGF receptor

Indexed keywords

SOMATOMEDIN C RECEPTOR;

ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN TISSUE; IGF1R GENE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR UPREGULATION; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RETROSPECTIVE STUDIES; UP-REGULATION;

EID: 79955411449     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09556.x     Document Type: Article

References (67)

1. Cancer Research UK statistics. 2009; Available at:. Accessed August 2009
2. Loblaw DA, Virgo KS, Nam R, et al,. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-605 (Pubitemid 46733088)
3. Denis L, Murphy GP,. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993; 72 (Suppl. 12): 3888-95 (Pubitemid 23361549)
4. Eisenberger MA, Blumenstein BA, Crawford ED, et al,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42 (Pubitemid 28457865)
5. Tannock IF, de Wit R, Berry WR, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
6. Petrylak DP, Tangen CM, Hussain MH, et al,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 (Pubitemid 39315318)
7. Collins R, Fenwick E, Trowman R, et al,. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007; 11: iii-iv, xv- xviii, 1- 179
8. Mancuso A, Oudard S, Sternberg CN,. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 2007; 61: 176-85 (Pubitemid 46091748)
9. Samani AA, Yakar S, LeRoith D, Brodt P,. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47 (Pubitemid 46220849)
10. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM,. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008; 14: 6364-70
11. Chan JM, Stampfer MJ, Giovannucci E, et al,. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6 (Pubitemid 28067285)
12. Stattin P, Bylund A, Rinaldi S, et al,. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 1910-7 (Pubitemid 32036921)
13. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB,. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 4258-65 (Pubitemid 32055383)
14. Finne P, Auvinen A, Koistinen H, et al,. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000; 85: 2744-7 (Pubitemid 32269145)
15. Wolk A, Mantzoros CS, Andersson SO, et al,. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-5 (Pubitemid 28304159)
16. Chokkalingam AP, Pollak M, Fillmore CM, et al,. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001; 10: 421-7 (Pubitemid 32701626)
17. Shi R, Berkel HJ, Yu H,. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001; 85: 991-6 (Pubitemid 33016002)
18. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M,. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-53 (Pubitemid 38529873)
19. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR,. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996; 81: 3774-82 (Pubitemid 26339953)
20. Chott A, Sun Z, Morganstern D, et al,. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999; 155: 1271-9 (Pubitemid 29488934)
21. Zhang P, Wang-Rodriguez J, Bailey D,. Insulin-like growth factor receptor expression in prostate cancer. Am J Clin Pathol 1999; 112: 130
22. Figueroa JA, De Raad S, Speights VO, Rinehart JJ,. Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters. Cancer Invest 2001; 19: 28-34 (Pubitemid 32233799)
23. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V,. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003; 23: 3825-35 (Pubitemid 37479239)
24. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM,. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-50 (Pubitemid 34525783)
25. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P,. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 2004; 202: 50-9 (Pubitemid 38072845)
26. Krueckl SL, Sikes RA, Edlund NM, et al,. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004; 64: 8620-9 (Pubitemid 39552075)
27. Liao Y, Abel U, Grobholz R, et al,. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 2005; 36: 1186-96 (Pubitemid 41540395)
28. Sroka IC, McDaniel K, Nagle RB, Bowden GT,. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. Prostate 2008; 68: 463-76 (Pubitemid 351500207)
29. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D,. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004; 23: 786-94 (Pubitemid 38241279)
30. Pandini G, Genua M, Frasca F, Vigneri R, Belfiore A,. Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway. Ann N Y Acad Sci 2009; 1155: 263-7
31. Narita S, Tsuchiya N, Saito M, et al,. Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis. Prostate 2008; 68: 321-35 (Pubitemid 351273061)
32. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M,. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986; 261: 12665-74 (Pubitemid 17204223)
33. Rubin J, Chung LW, Fan X, et al,. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. Prostate 2004; 58: 41-9 (Pubitemid 38057987)
34. Bhattacharyya RS, Stern PH,. IGF-I and MAP kinase involvement in the stimulatory effects of LNCaP prostate cancer cell conditioned media on cell proliferation and protein synthesis in MC3T3-E1 osteoblastic cells. J Cell Biochem 2003; 90: 925-37 (Pubitemid 37467108)
35. Goya M, Miyamoto S, Nagai K, et al,. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004; 64: 6252-8 (Pubitemid 39129428)
36. Greenberg NM, DeMayo F, Finegold MJ, et al,. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92: 3439-43
37. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM,. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999; 59: 2203-9 (Pubitemid 29217686)
38. Damon SE, Plymate SR, Carroll JM, et al,. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 2001; 142: 21-7 (Pubitemid 32183661)
39. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL,. Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 1997; 138: 1728-35 (Pubitemid 27137128)
40. Reiss K, Wang JY, Romano G, et al,. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 2000; 19: 2687-94 (Pubitemid 30326418)
41. Soos M, Field C, Lammers R, et al,. A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem 1992; 267: 12955-63
42. Baker J, Liu JP, Robertson EJ, Efstratiadis A,. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82 (Pubitemid 23306022)
43. Bohula EA, Salisbury AJ, Sohail M, et al,. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem 2003; 278: 15991-7 (Pubitemid 36799718)
44. Hellawell G, Ferguson D, Brewster S, Macaulay V,. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 2003; 91: 271-7 (Pubitemid 36232849)
45. Sell C, Dumenil G, Deveaud C, et al,. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994; 14: 3604-12 (Pubitemid 24160768)
46. Turner BC, Haffty BG, Narayanan L, et al,. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079-83 (Pubitemid 27351714)
47. Macaulay VM, Salisbury AJ, Bohula EA, Playford MP, Smorodinsky NI, Shiloh Y,. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 2001; 20: 4029-40 (Pubitemid 32681608)
48. Yeh AH, Bohula EA, Macaulay VM,. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 2006; 25: 6574-81 (Pubitemid 44646185)
49. Yuen JS, Cockman ME, Sullivan M, et al,. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 2007; 26: 6499-508 (Pubitemid 47530598)
50. Yuen JS, Akkaya E, Wang Y, et al,. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 2009; 8: 1448-59
51. Parker AS, Cheville JC, Janney CA, Cerhan JR,. High expression levels of insulin-like growth factor-I receptor predict poor survival among women with clear-cell renal cell carcinomas. Hum Pathol 2002; 33: 801-5 (Pubitemid 34983100)
52. Parker AS, Cheville JC, Blute ML, Igel T, Lohse CM, Cerhan JR,. Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival. Cancer 2004; 100: 2577-82 (Pubitemid 38715762)
53. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR,. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-6 (Pubitemid 29418745)
54. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR,. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006; 99: 392-401 (Pubitemid 44435557)
55. Plymate S, Tennant M, Culp S, et al,. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 2004; 61: 276-90 (Pubitemid 39350451)
56. Pandini G, Mineo R, Frasca F, et al,. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005; 65: 1849-57 (Pubitemid 40478613)
57. Gregory CW, He B, Johnson RT, et al,. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-9 (Pubitemid 32685750)
58. Gioeli D, Black BE, Gordon V, et al,. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 2006; 20: 503-15 (Pubitemid 43291205)
59. Plymate SR, Haugk K, Coleman I, et al,. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007; 13: 6429-39 (Pubitemid 350075033)
60. Sutherland BW, Knoblaugh SE, Kaplan-Lefko PJ, Wang F, Holzenberger M, Greenberg NM,. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res 2008; 68: 3495-504
61. Chiaverotti T, Couto S, Donjacour A, et al,. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008; 172: 236-46 (Pubitemid 351186384)
62. Huss W, Gray D, Tavakoli K, et al,. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007; 9: 938-50 (Pubitemid 350086439)
63. Iwamura M, Sluss P, Casamento J, Cockett A,. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993; 22: 243-52 (Pubitemid 23184735)
64. Krueckl S, Sikes R, Edlund N, et al,. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004; 64: 8620-9 (Pubitemid 39552075)
65. Nickerson T, Chang F, Lorimer D, Smeekens S, Sawyers C, Pollak M,. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 61: 6276-80 (Pubitemid 32762567)
66. DiGiovanni J, Kiguchi K, Frijhoff A, et al,. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A 2000; 97: 3455-60 (Pubitemid 30183324)
67. Aleksic T, Chitnis MM, Perestenko OV, et al,. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 2010; 70: 6412-9